Evommune is holding a webcast about EVO570, an investigational oral drug candidate it licensed from China’s Hinova Pharmaceuticals, and how the program fits into its broader immunology pipeline. The announcement is a pipeline update, not a new transaction announcement: it gives no financial terms for the license.
The pre-recorded webcast was scheduled to be available at 8:30 a.m. ET on Nov. 5, with CEO Luis Peña and other executives discussing the drug’s biology, preclinical profile and planned development in rheumatoid arthritis.
- What EVO570 is: The candidate is designed to direct VAV1, an immune-cell signaling protein involved in both T-cell and B-cell receptor pathways, to the cell’s protein-disposal machinery for degradation. Evommune describes it as an oral molecular glue degrader.
- License scope: Under an agreement announced previously, Evommune has exclusive worldwide rights to develop, manufacture and commercialize EVO570 outside Greater China. The candidate was previously called HC118 and is known as HP570 in Greater China.
- What management planned to cover: The webcast was to address VAV1 biology, EVO570’s preclinical profile, its planned development path in rheumatoid arthritis, the license transaction and the candidate’s place in Evommune’s immunology pipeline. The announcement does not provide the transaction’s financial terms.
- Access to the event: The webcast was to be posted on Evommune’s investor-relations website, with a replay available for 30 days. There would be no live question-and-answer session; investors could send questions to the company’s investor-relations team.
- Development status: EVO570 remains investigational and has not been approved by any regulatory authority.
The license gives Evommune development and commercialization rights to EVO570 across markets outside Greater China, adding a VAV1-targeting candidate to its immunology portfolio. The announcement provides no new clinical data or specific development milestones.